Nishimoto Norihiro
Laboratory of Immune Regulation, Wakayama Medical University.
Clin Calcium. 2009 Mar;19(3):425-31.
Tocilizumab has been shown to have strong effect to retard the progression of structural joint damage in patients with rheumatoid arthritis. It was approved not only for signs and symptoms but also structural joint damage of rheumatoid arthritis in Japan. In this review, the efficacy, utility, positioning, and the future prospect will be discussed.
托珠单抗已被证明对延缓类风湿性关节炎患者关节结构损伤的进展具有显著效果。在日本,它不仅被批准用于治疗类风湿性关节炎的体征和症状,还被批准用于治疗关节结构损伤。在本综述中,将讨论其疗效、实用性、定位及未来前景。